UPDATED: In bid to remake itself after pancreatic cancer flop, Halozyme acquires Antares and its drug delivery tech for $960M - Endpoints News

After the market hibernated for much of the first quarter, things are starting to get moving as the calendar turns toward Q2. And following the big news of GlaxoSmithKline’s Sierra buyout earlier Wednesday, another biotech deal landed to give the M&A seekers …

Nearly every clinical trial, regardless of indication or phase, should be agile—incorporating technology and decentralized approaches—to make drug and therapy development faster, easier and more repr… [+553 chars]

full article...